ProCE Banner Activity

New Mechanisms, New Medications for Psychosis

Slideset

This presentation reviews the evidence showing antipsychotic properties can be conferred by agents that do not bind to D2 receptors; the preclinical and clinical evidence underlying the antipsychotic mechanisms underlying 5-HT2A antagonism, muscarinic M4 agonism, and TAAR1 agonism; and how TAAR1 agonists modulate activity at presynaptic and postsynaptic D2 receptors via a G-protein independent pathway (Akt/β-arrestin2/glycogen synthase kinase 3β).

Released: March 22, 2022

Expiration: March 21, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Jonathan M. Meyer

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Independent Educational Activity

Faculty Disclosure

Primary Author

Jonathan M. Meyer, MD

Voluntary Clinical Professor of Psychiatry
University of California, San Diego
Distinguished Life Fellow
American Psychiatric Association
San Diego, California

Jonathan M. Meyer, MD, has disclosed that he has received consulting fees from Acadia, Alkermes, Intracellular Therapeutics, and Neurocrine and fees for non-CME/CE services from Acadia, Alkermes, Intracellular Therapeutics, Neurocrine, Noven, Otsuka, and Sunovion.